Tatva chintan pharma Chem Limited has formally notified stock exchanges that it does not qualify as a Large Corporate under the Securities and Exchange Board of India's debt securities framework. The confirmation was submitted to both BSE Limited and National Stock Exchange of India Limited on April 29, 2026.

Regulatory Compliance and Framework

The disclosure was made pursuant to SEBI Master Circular SEBI/HO/DDHS/DDHS-PoD/P/CIR/2025/0000000137 dated October 15, 2025, read with Chapter XII of SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, and SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. These regulations govern fund raising by issuance of debt securities by Large Corporates and require entities to make initial disclosures within 30 days from the beginning of the financial year.

Financial Position and Credit Profile

As part of the mandatory disclosure requirements, Tatva Chintan Pharma Chem provided detailed information about its financial standing and creditworthiness:

The company's outstanding borrowing of Rs. 6.04 crores as of March 31, 2026, falls below the threshold criteria that would classify it as a Large Corporate under the SEBI framework. The credit ratings assigned by CRISIL Ratings Limited reflect the company's creditworthiness, with BBB+/Stable indicating adequate safety for long-term obligations and A2 representing good safety for short-term obligations.

Regulatory Implications

By confirming its non-Large Corporate status, Tatva Chintan Pharma Chem is exempt from the mandatory borrowing requirements through debt securities that apply to Large Corporates. The SEBI framework requires Large Corporates to raise a specified portion of their incremental borrowings through debt securities markets rather than traditional bank loans.

The disclosure was signed by Company Secretary and Compliance Officer Ishwar Nayi and Chief Financial Officer Ajesh Pillai, ensuring proper authorization and compliance with regulatory requirements. This confirmation allows the company to continue its current financing structure without the additional compliance obligations imposed on Large Corporates under the SEBI debt securities framework.

Tatva chintan pharma Chem Limited has filed its quarterly compliance certificate for the quarter ended March 31, 2026, in accordance with SEBI regulatory requirements. The company submitted the mandatory documentation to stock exchanges and depositories on April 6, 2026.

Regulatory Compliance Filing

The compliance certificate was filed pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. Company Secretary and Compliance Officer Ishwar Nayi signed and submitted the documentation to relevant regulatory bodies.

Registrar Confirmation

MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, serves as the company's registrar and share transfer agent. The registrar issued the compliance certificate on April 3, 2026, confirming proper handling of dematerialisation processes during the quarter.

The registrar confirmed that securities received from depository participants for dematerialisation during the quarter ended March 31, 2026, were properly processed and confirmed to the depositories. All security certificates received for dematerialisation were verified, mutilated, and cancelled following due verification procedures.

Depository Operations

The compliance certificate covers the company's adherence to prescribed timelines for depository operations. Key confirmations include:

• Securities received for dematerialisation were accepted or rejected within regulatory timelines
• Security certificates comprised in dematerialisation requests have been listed on stock exchanges where existing securities are traded
• Names of depositories have been substituted in the register of members as registered owners
• All verification procedures were completed by depository participants as required

Regulatory Distribution

The compliance certificate was distributed to multiple regulatory bodies and stock exchanges. Recipients included BSE Limited, National Stock Exchange of India Limited, National Securities Depository Limited, and Central Depositories Services (India) Limited.

The company confirmed that the compliance information would be uploaded on its official website for public access, ensuring transparency in regulatory compliance matters.